MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck Kgaa Spns/Adr (OP:MKKGY)

30.42 +0.18 (+0.60%)
Streaming Delayed Price Updated: 3:58 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 122,724
Open 30.11
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 30.24
Today's Range 30.11 - 30.53
52wk Range 24.32 - 31.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
EMD Serono, CVS Health To Partner On TrumpRx Fertility Program Launching In 2026 ↗
Trump and EMD Serono strike a deal to cut fertility drug costs, expand U.S. manufacturing, and launch the TrumpRx Fertility program in 2026. 
Via Benzinga
Topics Government

Performance

YTD
+6.8%
+6.8%
1 Month
+3.4%
+3.4%
3 Month
+16.9%
+16.9%
6 Month
+17.4%
+17.4%
1 Year
+6.9%
+6.9%

More News

Read More
News headline image
Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts ↗
Via Benzinga
News headline image
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support
From Crown Bioscience
Via JCN Newswire
News headline image
Germany's Merck To Launch Semiconductor Base In China ↗
Via Benzinga
News headline image
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗
Via Benzinga
News headline image
Germany's Merck In Talks To Buy Cancer Drug Maker SpringWorks Therapeutics ↗
Via Benzinga
Topics Intellectual Property
News headline image
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion ↗
Via Benzinga
News headline image
Pfizer Clears Required Regulatory Hurdles To Complete $43B Seagen Acquisition ↗
Via Benzinga
News headline image
Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis ↗
Via Benzinga
News headline image
Life Sciences Player Repligen's Strategic European Acquisition - What It Means for Investors ↗
Via Benzinga
News headline image
Merck Germany Reports 5% Decline In Q2 Sales, Expects More Decline In 2023 ↗
Via Benzinga
News headline image
Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List ↗
Via Benzinga
News headline image
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation ↗
Via Benzinga
News headline image
Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions ↗
Via Benzinga
News headline image
FDA Issues Partial Clinical Hold On Merck Germany's Multiple Sclerosis Study ↗
Via Benzinga
News headline image
Merck Germany Regains Exclusive Global Rights To Cancer Drug From Pfizer ↗
Via Benzinga
News headline image
Incyte Would Now Compete With Merck, Pfizer As Its Skin Cancer Treatment Scores FDA Accelerated Approval ↗
Via Benzinga
News headline image
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics ↗
Via Benzinga
News headline image
PDS Biotech, Merck Germany Enter Licensing Pact For Investigational Cancer Treatment ↗
Via Benzinga
News headline image
Mersana Inks Cancer Therapy Development Deal With Merck Germany ↗
Via Benzinga
News headline image
SpaceX Starlink's New In-Flight Connectivity Service, Amazon's NY Workers Reject Union, Celsius Network Faces Several Federal Investigations: Top Stories Wednesday, Oct. 19 ↗
Via Benzinga
News headline image
Germany's Merck Slapped With Formal French Investigation Related To Its Thyroid Drug ↗
Via Benzinga
News headline image
PDS Biotech Highlights Expanded Data From PDS0101 Triple Combination Trial In HPV-Positive Cancers ↗
Via Benzinga
News headline image
TSM Looks To Hire Over 8,000 People In 2022 ↗
Via Benzinga

Frequently Asked Questions

Is Merck Kgaa Spns/Adr publicly traded?
Yes, Merck Kgaa Spns/Adr is publicly traded.
What exchange does Merck Kgaa Spns/Adr trade on?
Merck Kgaa Spns/Adr trades on the OTC Traded
What is the ticker symbol for Merck Kgaa Spns/Adr?
The ticker symbol for Merck Kgaa Spns/Adr is MKKGY on the OTC Traded
What is the current price of Merck Kgaa Spns/Adr?
The current price of Merck Kgaa Spns/Adr is 30.42
When was Merck Kgaa Spns/Adr last traded?
The last trade of Merck Kgaa Spns/Adr was at 02/18/26 03:58 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story